drugset / Trial / NCT04435691
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 1/2
Terminated
110 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase Ib/II trial studies the side effects and best dose of magrolimab and venetoclax when given together with azacitidine and to see how well they work in treating patients with acute myeloid leukemia. Magrolimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving magrolimab, azacitidine, and venetoclax may help to control the disease.
Timeline
- Start
- 2020-07-28
- Primary completion
- 2025-03-25
- Completion
- 2025-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Magrolimab | Monoclonal antibody | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |